Hppk inhibitors useful as antibacterial agents
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Servi
InventorsXinhua Ji, Genbin Shi, Gary X. Shaw
Life of this patent
Estimating the term…
Abstract
The disclosure provides linked purine pterin compounds of Formula I that are novel inhibitors of HPPK, a kinase responsible for an essential step in the biosynthesis of folic acid. (Formula I) The variables, e.g., A1-A3, R1-R4, B1-B2, and L1 are defined in the disclosure. These linked purine pterin inhibitors bind to HPPK with high affinity and specificity. Pharmaceutical compositions containing the HPPK inhibitors and methods of treating a bacterial infection in a patient with one or more of the HPPK inhibitors of the disclosure are also provided.
Claims26
A compound or pharmaceutically acceptable salt thereof of the formula:
- wherein:
- is a 5 or 6-membered heterocyclic ring;
- X is nitrogen, —N(A5)-, —C(A6)-, or —C(A6A7)-;
- A1 is hydrogen, oxo, amino, or aminoC1-C2alkyl;
- A2 is absent, hydrogen, or C1-C2alkyl;
- A3 is absent, or one or two substituents independently chosen from hydrogen, halogen, C1-C2alkyl, and C1-C2alkoxy;
- A5 is hydrogen or C1-C4alkyl;
- A6 and A7 are independently hydrogen, C1-C4alkyl, or C1-C4alkoxy;
- R1 is C1-C4alkylene optionally substituted with hydroxyl, halogen, C1-C2alkyl, or oxo;
- R2 is chosen from —NH—, —NHC(═O)—, —SH—, —S(═O)—, —S(═O)2—, —P(═O)—, and —P(═O)2—;
- R3 is —N(R5—), —C1-C4alkyl)N(R5)—, or —C1-C4alkyl)C(O)N(R5)—, where R5 is alkyl substituted with —P(O)(OH)2, —OP(O)(OH)2, or —COOH;
- R3 is a 5- or 6-membered heterocycloalkyl containing 1 or 2 heteroatoms independently chosen from N, O, and S, which 5- or 6-membered heterocycloalkyl is unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, —COOH, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy;
- or
- R3 is —(C1-C4alkyl)heterocycloalkyl;
- which heterocycloalkyl is a 5- or 6-membered heterocycloalkyl containing 1 or 2 heteroatoms independently chosen from N, O, and S, and is substituted with at least one —(C0-C4alkyl)P(O)(OH)2, —(C0-C4alkyl)OP(O)(OH)2, —(C0-C4alkyl)COOH, or —(C0-C4alkyl)C(═O)O(C1-C4alkyl) and optionally substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, —COOH, C1-C4alkyl, C1-C4alkoxy, mono- and di-C1-C4alkylamino, C1-C2haloalkyl, and C1-C2haloalkoxy;
- L1 is an alkylene linker having from 1 to 4 carbon atoms and containing 1 group selected from —O—, —NH—, —S—, —S(═O)—, —S(═O)2—, —S(═O)2NH—, —C(═O)NH—, —P(═O)—, and —P(═O)2—;
- and optionally containing 1 to 2 carbon-carbon double bonds, wherein L1 is unsubstituted or substituted with 1 or more substituents independently chosen from hydroxyl, halogen, amino, C1-C4alkyl, C1-C4alkoxy, C1-C2haloalkyl, and C1-C2haloalkoxy;
- is a 5- or 6-membered monosaccharide ring;
- and
- B1 and B2 are independently chosen from hydrogen, halogen, hydroxyl, amino, C1-C2alkyl, C1-C2alkoxy, mono- or di-C1-C2alkylamino, aminoC1-C2alkyl, C1-C2haloalkyl, and C1-C2haloalkoxy.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.